NCT07340658 2026-01-14
SIE-3
Rovi Pharmaceuticals Laboratories
Phase 3 Not yet recruiting
Clinical Trials
7 trialsNCT07299890 2025-12-23
An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer
Anhui Provincial Cancer Hospital
Phase 2 Not yet recruiting
NCT06962969 2025-06-10
A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database
Pfizer
Not yet recruiting
NCT06810492 2025-03-17
The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment
Hubei Cancer Hospital
Phase NA Not yet recruiting
NCT06757335 2025-01-03
A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer
Hinova Pharmaceuticals Inc.
Phase 1/2 Not yet recruiting
NCT06338644 2024-03-29
Palbociclib
Helwan University
Not yet recruiting
NCT06076772 2023-10-11
Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients
Assiut University
Not yet recruiting